SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

SciSparc to conduct trial at Yale University in the USA, Tel Aviv Sourasky Medical Center in Israel and the Hannover Medical School in Germany TEL AVIV, Israel, Nov. 10, 2023 -- SciSparc Ltd. , a...

Related Keywords

Germany ,United States ,Israel ,Hannover ,Niedersachsen ,Israeli , ,Drug Administration ,Institute For Drugs ,Nasdaq ,Exchange Commission ,Yale University ,Tel Aviv Sourasky Medical Center ,Scisparc Ltd ,Hannover Medical School ,Company Phase ,Israeli Ministry Of Health ,Tourette Syndrome ,Federal Institute ,Medical Devices ,Israeli Ministry ,Hannover Medical ,Yale Global Tic Severity Scale ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,